Rain Therapeutics Inc. Profile Avatar - Palmy Investing

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …

Biotechnology
US, Newark [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of RAIN's Analysis
CIK: 1724979 CUSIP: 75082Q105 ISIN: US75082Q1058 LEI: - UEI: -
Secondary Listings
RAIN has no secondary listings inside our databases.